Abstract: Disclosed are compositions and methods for reducing blood alcohol content following alcohol consumption. The inventive compositions and methods rapidly reduce blood alcohol content and alleviate symptoms of intoxication in a subject having an elevated blood alcohol content due to alcohol consumption.

Abstract: The present invention provides our new isolate Lactiplantibacillus plantarum SNI3 bacterial strain, deposited as NCAIM (P) B 001482, formulation based on SNI3 strain, application of formulation on male vertebrates, breeding male and human males to favorably change their behavior and lean body mass, to decrease body fat content and increase their reproductive fitness, sperm number and testosterone level.

Abstract: A kit is disclosed, for the destruction of cancer cells with stem cell properties based on the oncolytic action of the Zika virus, associated with the aggressiveness of malignant tumors and an unfavorable clinical prognosis, especially in malignant tumors of the nervous system. The kit contains a pharmaceutical composition, sterile glass vials with a rubber seal, and syringes with sterile and disposable needles for injection.

Abstract: Provided are compositions and methods for prophylaxis or therapy of cancer. The compositions and methods include use of Birnaviridae double stranded RNS (dsRNA) viruses for treating cancer in individuals that are not the normal virus hosts. Modifications of the dsRNA viruses are provided and include genetic changes that result improvements in anti-cancer therapy by increasing onxotoxicity of the modified viruses, and by including sequences encoding therapeutic pay loads.

Abstract: A composition for use in modulating immune responses in a subject in need thereof. The composition of the invention includes a fructo-oligosaccharide composition, and an extract of parietal saccharides and an extract of parietal saccharides from at least one Cyberlindnera species and at least one Saccharomyces species including mannans, mannan-oligosaccharides, beta 1,3 glucans, chitin, beta 1,6 glucans, or mixtures thereof, the weight ratio of fructo-oligosaccharide composition to the extract of parietal saccharides being at least 2. Also, the composition as such as well as its use in feed and food and nutraceutical applications.

Abstract: The current invention relates to a method for extracting biological material for obtaining cosmetic and/or pharmaceutical components in the obtained extract using an extraction solvent, comprising the steps of contacting the biological material with the extraction solvent, immersing the biological material in the extraction solvent, macerating or percolating or infusing the mixture, filtering and/or centrifuging the extraction product obtained, thereby obtaining a liquid extract, wherein said extraction solvent comprises water and one or a plurality of alkane diols with 5 through 12 carbon atoms. The invention also relates to a cosmetic preparation and use of a composition.

Abstract: The present invention relates to a composition comprising an elderberry extract as an effective component for preventing, treating, or alleviating andropause syndrome, wherein the elderberry extract of the present invention increases testosterone secretion in sperm cells and andropause syndrome animal models, and thus can be usefully employed as a pharmaceutical or food composition for preventing, treating or alleviating andropause syndrome.

Abstract: The present invention relates to a di Cinnamomum zeylanicum EO, or to an association comprising said EO and one or more antitumour drug, for use in the treatment or in adjuvating the treatment of melanoma. The invention relates also to a pharmaceutical composition comprising said EO or said association and at least a pharmaceutically acceptable carrier for use in the treatment or in adjuvating the treatment of melanoma.

Abstract: The therapeutic product invention states to the use of quantified solutions containing natural compounds of cannabidiol, CBDa, cannabigerol, CBGa combined with Uncaria tomentosas' hydroalcoholic extracts emulsified in saline solution in homogenous mixture administered intranasally. A natural respiratory immune booster with mechanisms against respiratory viruses and foreign substances (e.g. SARS-Cov-2 spike protein, bacterial, allergen) including; inhibition, reduction, blockage of cellular entry, and encapsulation and expulsion with minute impact of variant lineage. By induction of the interferon pathway both directly and indirectly following activation of the host immune response to viral pathogen, suppressing cytokine activation in response to viral infection, as well as blocks viral replication after entry into cells.

Abstract: In one embodiment, the present application provides an herbal supplement and method for treating bloating, constipation and/or weight gain in a human subject comprising orally administering to a subject in need thereof an effective amount of the herbal supplement comprising a red quebracho extract. In other embodiments, the supplement may additionally include a triterpenoid saponin, an anti-spasmodic agent, or both.

Abstract: A method for regulating immunity is provided. The method includes administering to a subject in need thereof a composition that includes an effective dose of black hulless barley extract. The black hulless barley extract is obtained by extracting seeds of black hulless barley (Hordeum vulgare L. var. nudum Hook. f.) with an amylase aqueous solution.

Abstract: The present disclosure relates generally to a method of promoting cognitive function in a target subject by the administration of a dietary supplement composition. Additionally, the disclosure relates to a dietary supplement composition which promotes cognitive function. In particular, the dietary supplement composition comprises phosphatidylserine, coffee fruit extract and Alpinia galanga extract.

Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.

Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.

Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets.

Abstract: Embodiments of the instant disclosure generally relate to formulations for preserving, storing, administering and/or delivering Smad7 polypeptides or fragments thereof to a subject to reduce the risk of onset, or to prevent or treat a health condition. Certain embodiments relate to administering and/or delivering Smad7 formulations to treat a subject having adverse effects due to excessive inflammation, radiation, chemotherapy, other anti-tumor treatments, infection and/or necrosis. In some embodiments, a Smad7 polypeptide can include a Smad7 fragment as part of a fusion polypeptide formulated for topical or dermal delivery to a subject further including a gelling agent to improve efficacy of the formulation.

Abstract: The present invention provides a method to treat and/or prevent febrile neutropenia and Grade 3/4 neutropenia. The method comprises application a Declined mobilizing granulocyte colony-stimulating factor (De-mobilized G-CSF) at a selected time, and a controlled dosage depended on the severity of neutropenia. The present invention also provides evidences to identify the De-mobilized G-CSF and High-mobilized G-CSF, and a method for preparing the De-mobilized G-CSF.

Abstract: The present disclosure, relates, in general to methods for improving adverse events in subjects having a mature T cell lymphoma and who are receiving treatment with an anti-CD30 antibody drug conjugate in combination with accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.

Abstract: A composition of polyvinyl alcohol and a small molecule polyhydroxy compound is used as a substrate to prepare a microneedle having a strongly hydrophilic surface and a drug-loaded microneedle. The microneedle can be obtained by means of the compatibility of a polyhydroxy polymer polyvinyl alcohol and a small molecule polyhydroxy compound. The preparation of a blank microneedle and the drug loading are conducted in stages and the drug loading stage is not conducted at a high temperature. By means of the microneedle substrate composition, the blank microneedle prepared therefrom and the use of the blank microneedle in drug loading, the inherent surface strongly hydrophilic polarity of the polyvinyl alcohol is maintained, such that the drug-loading capacity and the in-vivo penetration capacity of the coated drug loading are significantly increased.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, wherein said pharmaceutical composition is administered no more frequent than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered every 24 hours required to maintain serum calcium within normal levels over said 24 hour period in humans.

Abstract: Aspects of the present disclosure relate generally to methods for treating neurodegenerative disorders with chimeric proteins and pharmaceutical compositions comprising such chimeric proteins.

Abstract: The invention relates to a pharmaceutical composition, which comprises Elapidae Phospholipase A2 and a pharmaceutically acceptable carrier thereof. This pharmaceutical composition can be used for the treatment of micro proteinuria and renal disfunction with increased ratio of urinary albumin vs creatinine of diabetes nephropathy patients, thereby controlling and delaying the pathological progress of kidney, improving the renal function, and has extremely potential for the treatment of diabetes nephropathy.

Abstract: The invention relates to methods for immunomodulation of immunosuppressive tumor cell microenvironment and prevention of tumor microbiome effects through multiple pathways with DNase enzyme therapy. Methods for immunomodulation of immunosuppressive tumor cell microenvironment comprising administering an effective amount of deoxyribonuclease (DNase) enzyme, either alone or in combination with other immunomodulating agent.

Abstract: The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.

Abstract: The present disclosure relates to Clostridium botulinum neurotoxin serotype A (BoNT/A) compositions with a plurality of 900 kDa Clostridium botulinum neurotoxin serotype A (BoNT/A) complex species. Provided herein are compositions comprising BoNT/A that have a low level of oxidation at specific methionine positions of 150 kDa BoNT/A. Further provided herein are methods of producing a composition comprising BoNT/A using a low temperature during the process of fermenting Clostridium botulinum bacteria.

Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Celiac disease. Also described herein is a method for treating a subject with Celiac disease using digestive enzymes and their derivatives to alleviate the symptoms of Celiac disease. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Celiac disease.

Abstract: The present disclosure is directed to systems, compositions and methods for promoting immune tolerance to an antigen in a subject. Systems and methods provide for introducing directly into at least one lymph node(s) of the subject a therapeutically effective amount of a composition comprising an antigen associated with an autoimmune disease or disorder, in combination with a carrier comprising an immune modulatory agent such that an immune response to said antigen is inhibited or suppressed in the subject. The present disclosure is also directed to systems, compositions and methods for the treatment and/or prevention of autoimmune diseases and conditions, and in particular type 1 diabetes and graft rejection.

Abstract: The invention relates to compositions comprising a nucleic acid that encodes a peptide or a peptide that induces an immune response in an animal or a mammal that is protective against infection by one or more pathogens. In addition, the invention relates to vaccines comprising compositions and to method for treating and preventing an infection in animals and mammals such as humans.

Abstract: The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA suitable for use in treatment and/or prophylaxis of an infection with Respiratory syncytial virus (RSV) or a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial RNA, compositions, and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial RNA, compositions and vaccines.

Abstract: The invention provides an ectromelia virus vector for expression of heterologous sequences under the control of a viral early/late promoter, and methods of use thereof for immunotherapy, cancer treatment and treatment of infectious disease.

Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.

Abstract: The disclosure provides a composition comprising CpG ODN and one or more other adjuvants that work together with the immunomodulatory CpG ODN, such as an aluminum adjuvant, wherein the CpG ODN comprises or consists of a nucleotide sequence selected from SEQ ID NOs: 1-4, wherein at least one nucleotide in the nucleotide sequence is a chemically modified nucleotide having a structure of formula (I): wherein, Y is S or O, R is H or a positively charged counterion, B is independently an unmodified or modified nucleobase, and R1 is H, F, CI, OH, OMe, Me, O-ethyloxymethyl. Use of the composition, a pharmaceutical composition comprising the composition, a preparation method thereof, and use of the pharmaceutical composition are also disclosed.

Abstract: A composition and method of preparing the composition is provided. The composition is for inhalation to treat respiratory syncytial virus. The composition includes a poly clonal antibody derived from human breastmilk. In particular, the composition includes intact antibodies representing more than about 81% of total antibodies. The total antibodies include intact antibodies and degraded antibodies.

Abstract: Provided is a novel therapeutic agent for inflammatory diseases such as autoimmune diseases. According to the present invention, an included IgG antibody comprises a human serum IgG antibody in which the sugar chain shown below is bonded to asparagine 297 (Asn297) in an Fe portion.

Abstract: The present invention relates to compositions and methods that reduce the level of pro-inflammatory cytokines, chemokines, and growth factors for inhibiting motor neuron degeneration and treating neurodegenerative disorders.

Abstract: Provided are a novel fully human antibody for human B7H3, a chimeric antigen receptor, and uses thereof; also provided are a novel fully human anti-human B7H3 antibody, a chimeric antigen receptor containing the antibody, and genetically engineered cells expressing the receptor and the antibody. It has been verified by experiments that CAR-T, CAR-NK and CAR-iNKT cells targeting B7H3 prepared on the basis of the present chimeric antigen receptor have relatively strong proliferation ability, cytokine release ability and tumor cell killing ability, and can effectively eliminate tumor cells.

Abstract: A bi-specific chimeric antigen receptor (bi-specific CAR) comprising a single chain variable fragment (scFv) and a single variable domain (VHH) in the extracellular antigen binding domain, wherein the scFv and VHH bind tumor associated antigens. Also provided herein are genetically engineered immune cells expressing such bi-specific CAR and therapeutic uses of the genetically engineered immune cells.

Abstract: A fluorocarbon emulsion in water for use in fractionated radiotherapy and chemotherapy, wherein said fluorocarbon comprises between 4 and 8 carbon atoms.

Abstract: The present invention provides a photodynamic therapeutic method to shorten the infectivity period of an infection caused by a targeted microorganism comprising: applying a photosensitizer on a targeted body treatment area; and applying light to the targeted body treatment area at a wavelength absorbed by the photosensitizer. The present invention also provides a method to induce a sustained humoral and cellular T-Cell responses against an antigen of a targeted microorganism comprising: applying a photosensitizer on a targeted body treatment area; and applying light to the targeted body treatment area at a wavelength absorbed by the photosensitizer.

Abstract: I present here new methods and theory about cancer and cancer treatment/curing also skin rushes.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: Provided is a composition containing a buffer to be used at the time of labeling of a chelated targeting agent with 90Y, 153Sm, 165Dy, 165Er, 166Ho, or 177Lu. At least one kind of buffer selected from the group consisting of benzoic acid, maleic acid, fumaric acid, succinic acid, and salts thereof is incorporated in a composition containing a chelated targeting agent.

Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Abstract: The disclosure provides methods of determining an initial amount of surfactant to include in a liquid pharmaceutical composition comprising a protein, intended for administration to a subject as an IV admixture. The methods comprise determining the degradation rate of the surfactant, the minimum amount of surfactant whereby stability of the protein is maintained in IV admixture the end of shelf-life of the liquid pharmaceutical composition, and, based on the degradation rate, shelf-life, and minimum amount of surfactant, determining a target amount of surfactant to include in the composition at the time of formulation.

Abstract: Pharmaceutical compositions comprising poorly water-soluble drugs (PSDs) and sucrose acetate isobutyrate (SAIB). The compositions are amorphous solid solutions or amorphous solid dispersions where the PSDs are present in the molecular or the amorphous state in the SAIB. The PSDs in amorphous form in the amorphous solid solutions can be stable against crystallization on exposure to elevated temperature and humidity conditions. Oral dosage forms containing the compositions are characterized by a higher dissolution rate in water, a higher serum maximum concentration (Cmax), and/or a greater area under the curve (AUG) than an equivalent oral dosage form without the SAIB.

Abstract: This invention relates to the use of destructurized starch as a thickening agent in cosmetic, dermatological and pharmaceutical compositions, paints, phytosanitary products and detergents.

Abstract: Provided herein is a class of ionizable lipid compounds represented by formula ((IV?), or pharmaceutically acceptable salts, isotopic variants, tautomers or stereoisomers thereof. Also provided is a nanoparticle pharmaceutical composition comprising said compound, and the application of said compound and its composition in the delivery of nucleic acids.

Abstract: A compound represented by formula (I), formula (II), or formula (IV), or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof, for use in inhibiting metallo-?-lactamases.

Abstract: The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.